The FDA has approved Osvyrti (denosumab-desu), a biosimilar to Prolia (denosumab), and Jubereq (denosumab-desu), a biosimilar to Xgeva (denosumab).

Most countries involved in FDA drug-approval trials do not receive timely market authorization for the studied drugs.

Premature mortality increased among adults in the US between 2012 and 2022, particularly among Black individuals.

A large percentage of US adults report feelings of loneliness and isolation, with societal division intensifying these feelings.

Fibromyalgia severity scores showed modest seasonal variations, with higher widespread pain reported during autumn vs summer.

The ACR issued a 2025 guideline for the treatment of SLE that addressed treatment and management of specific organ system ...

The global incidence of RA increased between 1990 and 2021, with rates estimated to continue rising through 2040.

An analysis of kidney biopsies before and after obinutuzumab treatment of lupus nephritis showed histologic remission or near remission in a greater proportion of patients than had complete renal ...

COVID-19 diagnosis was linked to arterial thromboembolism, venous thromboembolism, thrombocytopenia, myocarditis and pericarditis.

Opioid prescription rates among patients with axSpA remained stable in the UK but declined significantly in the US after 2016, likely as a result of CDC guidelines.

The FDA is requesting labeling changes that would remove boxed warnings from all HRT products used to treat menopausal ...

Nonartricular pain — particularly widespread NAP — was linked to worse physical, emotional, and social well-being among adults with early RA.